US 12,269,813 B2
Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide monohydrate
Carina Leys, Stabroek (BE); Kristof Leonard Kimpe, Beerse (BE); Robert Michael Geertman, Maarheeze (NL); Haojuan Wei, Changzhou (CN); and Peng Zhou, Changzhou (CN)
Assigned to Janssen Pharmaceutica NV, Beerse (BE)
Appl. No. 17/431,447
Filed by Janssen Pharmaceutica NV, Beerse (BE)
PCT Filed Feb. 20, 2020, PCT No. PCT/EP2020/054485
§ 371(c)(1), (2) Date Aug. 17, 2021,
PCT Pub. No. WO2020/169736, PCT Pub. Date Aug. 27, 2020.
Claims priority of application No. PCT/CN2019/075834 (WO), filed on Feb. 22, 2019.
Prior Publication US 2022/0127249 A1, Apr. 28, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/14 (2006.01)
CPC C07D 401/14 (2013.01) [C07B 2200/13 (2013.01)] 13 Claims
OG exemplary drawing
 
1. A crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]-1H-pyrazole-4-carboxamide (Compound A) monohydrate:

OG Complex Work Unit Chemistry
wherein the crystalline form is Form III, producing an X-ray powder diffraction pattern comprising peaks at 16.4, 23.7 and 25.7 degrees two theta±0.2 degrees two theta.